A purging procedure for pantoprazole and 4-lumen catheters to prevent IV drug incompatibilities
- PMID: 20694515
- DOI: 10.1007/s11096-010-9422-9
A purging procedure for pantoprazole and 4-lumen catheters to prevent IV drug incompatibilities
Abstract
Objective of the study: The purpose of this prospective intervention study was to assess the number of patients with Y-site incompatibilities before and after implementation of quality improvement measures to prevent incompatibilities consisting of a focused instruction for pantoprazole as a drug frequently involved in incompatible drug pairs and of a recommendation to use 4-lumen instead of 3-lumen catheters to increase the number of available central infusion lines.
Setting: Cardiovascular intensive care unit where several standard operating procedures (SOPs) dealing with compatibility were already in place.
Method: In a prospective intervention study, patients' IV medication was assessed for potential incompatibilities using a database containing compatibility information on approximately 60,000 drug pairs. In a first period, routine administration was monitored in 53 consecutive patients (control group). Then, quality improvement measures were implemented recommending a purging procedure before and after bolus administration of pantoprazole as a drug frequently causing incompatibilities in this setting. Additionally, the use of 4-lumen instead of 3-lumen catheters was suggested whenever considered useful by the responsible physicians. The monitoring was repeated during a second period in another 58 patients consecutively admitted to the same unit (intervention group).
Main outcome measure: Overall number of patients with at least one incompatible drug pair and number of patients receiving incompatible pantoprazole combinations.
Results: The number of patients receiving incompatible pantoprazole combinations decreased from 15 of the 15 patients receiving pantoprazole (100.0%) in controls to 9/16 (56.2%) in the intervention group (P < 0.01). The overall number of patients with incompatibilities was not influenced by the intervention with 36/58 (62.1%) compared to controls with 38/53 (71.7%, P = 0.28). The fraction of central lines contributed by four lumen central catheters was larger due to the intervention (80/168 lines, 47.6%) compared to controls (16/184, 8.7%, P < 0.001). Only sporadically there were incompatible combinations of drugs governed by the already existing SOPs.
Conclusion: In an intensive care setting with good SOP adherence, purging before and after administration decreased the respective incompatibility rate whereas the use of 4-lumen instead of 3- lumen catheters had not the expected benefit on separating drug pairs.
Similar articles
-
Avoiding incompatible drug pairs in central-venous catheters of patients receiving critical care: an algorithm-based analysis and a staff survey.Eur J Clin Pharmacol. 2023 Aug;79(8):1081-1089. doi: 10.1007/s00228-023-03509-0. Epub 2023 Jun 7. Eur J Clin Pharmacol. 2023. PMID: 37284873 Free PMC article.
-
Strategies to prevent drug incompatibility during simultaneous multi-drug infusion in intensive care units: a literature review.Eur J Clin Pharmacol. 2021 Sep;77(9):1309-1321. doi: 10.1007/s00228-021-03112-1. Epub 2021 Mar 25. Eur J Clin Pharmacol. 2021. PMID: 33768303 Review.
-
Prevention of intravenous drug incompatibilities in an intensive care unit.Am J Health Syst Pharm. 2008 Oct 1;65(19):1834-40. doi: 10.2146/ajhp070633. Am J Health Syst Pharm. 2008. PMID: 18796425
-
Intravenous Drug Incompatibilities in the Intensive Care Unit of a Tertiary Care Hospital in India: Are they Preventable?J Res Pharm Pract. 2020 Jun 26;9(2):106-111. doi: 10.4103/jrpp.JRPP_20_11. eCollection 2020 Apr-Jun. J Res Pharm Pract. 2020. PMID: 33102385 Free PMC article.
-
Nanomedicine: a new paradigm to overcome drug incompatibilities.J Pharm Pharmacol. 2020 Oct;72(10):1289-1305. doi: 10.1111/jphp.13292. Epub 2020 May 21. J Pharm Pharmacol. 2020. PMID: 32436221 Review.
Cited by
-
Avoiding incompatible drug pairs in central-venous catheters of patients receiving critical care: an algorithm-based analysis and a staff survey.Eur J Clin Pharmacol. 2023 Aug;79(8):1081-1089. doi: 10.1007/s00228-023-03509-0. Epub 2023 Jun 7. Eur J Clin Pharmacol. 2023. PMID: 37284873 Free PMC article.
-
Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility.Pharmaceutics. 2023 Aug 1;15(8):2069. doi: 10.3390/pharmaceutics15082069. Pharmaceutics. 2023. PMID: 37631283 Free PMC article.
-
Strategies to prevent drug incompatibility during simultaneous multi-drug infusion in intensive care units: a literature review.Eur J Clin Pharmacol. 2021 Sep;77(9):1309-1321. doi: 10.1007/s00228-021-03112-1. Epub 2021 Mar 25. Eur J Clin Pharmacol. 2021. PMID: 33768303 Review.
-
Incompatible intravenous drug combinations and respective physician and nurse knowledge: a study in routine paediatric intensive care.Eur J Hosp Pharm. 2019 Jul;26(4):214-217. doi: 10.1136/ejhpharm-2017-001248. Epub 2017 Jul 24. Eur J Hosp Pharm. 2019. PMID: 31338170 Free PMC article.
-
Safeguarding the process of drug administration with an emphasis on electronic support tools.Br J Clin Pharmacol. 2013 Sep;76 Suppl 1(Suppl 1):25-36. doi: 10.1111/bcp.12191. Br J Clin Pharmacol. 2013. PMID: 24007450 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials